Optimizing Aimovig Prior Authorizations via Waystar Clearinghouse Integration
Navigating prior authorizations for specialty medications like Aimovig through the Waystar Clearinghouse can be complex. Klivira streamlines this process, ensuring efficient submission and tracking for CGRP receptor antagonists.
Revenue cycle teams frequently encounter challenges with specialty drug prior authorizations, particularly when managing pharmacy benefit medications. The unique requirements of drugs like Aimovig, combined with clearinghouse workflows, demand a precise and automated approach to minimize denials and accelerate patient access.
Aimovig Prior Authorization Pathways within Waystar Workflows
Aimovig (erenumab), a CGRP receptor antagonist for migraine prevention, typically falls under the pharmacy benefit. This necessitates electronic prior authorization (ePA) submissions, often utilizing the NCPDP SCRIPT standard, which Waystar Clearinghouse facilitates. While less common for Aimovig, medical benefit submissions for certain CGRP inhibitors would typically leverage the X12 278 transaction set. Klivira ensures the correct pathway is identified and executed, routing requests to specialty pharmacies as required.
Common Formulary and Step-Therapy Hurdles for Erenumab
- **Failed Prior Therapies:** Payers frequently require documentation of failed trials with generic oral preventive medications (e.g., beta-blockers, tricyclic antidepressants, anticonvulsants).
- **Diagnosis Specificity:** Authorization may hinge on clear differentiation between chronic and episodic migraine diagnoses, often requiring specific ICD-10 codes and supporting clinical notes.
- **Quantity Limits and Duration:** Payer policies often impose limits on dosage or the initial approval duration, requiring re-authorization after a specified period.
- **Formulary Restrictions:** Aimovig may be positioned on a non-preferred tier or require a specific sequence of CGRP antagonist trials before approval.
- **Specialty Pharmacy Requirements:** Many payers mandate dispensing through designated specialty pharmacies, which must be coordinated during the PA process.
Essential Documentation for Aimovig PA Submissions via Waystar
Accurate and comprehensive documentation is critical for Aimovig prior authorization. This typically includes detailed patient history, a history of failed migraine preventive treatments (drug names, dosages, duration, reasons for failure), migraine frequency logs or diaries, and physician's notes supporting the diagnosis and medical necessity. Klivira's integration with EMRs extracts these data points, structuring them for efficient transmission through Waystar and adherence to payer-specific requirements.
Klivira's Role in Automating Aimovig ePA through Waystar Integration
Klivira directly integrates with your EMR via SMART on FHIR to pull relevant clinical data, then intelligently populates ePA forms for Aimovig. These requests are then submitted through Waystar Clearinghouse, leveraging its robust connectivity to payers. This automation minimizes manual data entry, reduces human error, and ensures that all required fields and attachments are accurately transmitted, accelerating the entire prior authorization lifecycle.
Benefits of Automated Aimovig PA Processing with Klivira
- Reduced administrative burden on PA coordinators.
- Accelerated turnaround times for Aimovig prior authorizations.
- Improved first-pass approval rates by ensuring complete and accurate submissions.
- Real-time tracking and status updates within your existing Waystar workflow.
- Proactive identification of re-authorization needs for continuity of care.
Navigating Pharmacy vs. Medical Benefit for CGRP Antagonists
While Aimovig primarily falls under the pharmacy benefit, other CGRP receptor antagonists may be covered under the medical benefit, requiring different submission protocols. Klivira's platform is designed to identify the correct benefit pathway, whether it's an NCPDP SCRIPT ePA for pharmacy benefit drugs like Aimovig or an X12 278 submission for medical benefit therapies, ensuring compliance with payer guidelines and efficient processing through Waystar.
Frequently asked questions
How does Klivira handle Aimovig's pharmacy benefit PA through Waystar?
Klivira automates the electronic prior authorization (ePA) process for Aimovig, which is typically a pharmacy benefit drug. Our system generates and submits the ePA request using the NCPDP SCRIPT standard directly through Waystar Clearinghouse, ensuring it reaches the appropriate payer for review and approval.
What are the most common reasons for Aimovig PA denials, and how does Klivira help?
Common reasons for Aimovig PA denials include insufficient documentation of failed prior therapies, incorrect diagnosis codes, or failure to meet payer-specific formulary criteria. Klivira helps by structuring and validating data pulled from your EMR, ensuring all required clinical evidence is included and presented correctly to align with payer guidelines before submission via Waystar.
Can Klivira integrate with our EMR to pull Aimovig-specific clinical data?
Yes, Klivira utilizes SMART on FHIR standards to integrate seamlessly with most EMR systems. This allows our platform to securely extract relevant patient data, such as diagnosis history, medication lists, and prior treatment failures, directly from your EMR to populate Aimovig prior authorization requests.
How does Klivira manage Aimovig re-authorizations?
Klivira proactively tracks the approval status and expiration dates for Aimovig prior authorizations. Our system can alert your team when a re-authorization is due and can initiate the automated submission process, leveraging previously approved data and updated clinical information to ensure continuity of patient care without interruption.
Does Klivira support all payers accessible via Waystar for Aimovig?
Klivira's platform is designed to maximize payer connectivity, working in conjunction with Waystar Clearinghouse's extensive network. We support ePA submissions for a vast majority of commercial and government payers for specialty drugs like Aimovig, continuously updating our rulesets to reflect current payer requirements and formularies.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo